GlassScriptPhysician profile
Lauren M Hendricks
NPI 1538598461
$16,951.08
in general payments reported to CMS, 2019-2025
61 companies · $3,633 in 2025
The $3,633 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,829 · 2022: $3,192 · 2023: $3,850 · 2024: $3,447 · 2025: $3,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,930.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,544.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,018.74 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,771.21 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Corcept Therapeutics | $1,051.59 | 2021-2025 | Korlym |
| Amgen INC. | $782.89 | 2021-2025 | Tepezza, Prolia, Evenity |
| Mannkind Corporation | $644.40 | 2021-2025 | Afrezza |
| Abbvie INC. | $556.36 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $492.19 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $469.71 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Cequr Corporation | $440.85 | 2022-2025 | Cequr Simplicity |
| Antares Pharma, INC. | $429.83 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $421.40 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $383.28 | 2021-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $376.52 | 2022-2025 | |
| Horizon Therapeutics Plc | $376.42 | 2021-2023 | Tepezza |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $371.32 | 2021-2024 | Tirosint, Licart, Licart |
| Esperion Therapeutics, INC. | $358.38 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $333.35 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.16 | 2021-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $255.39 | 2021-2025 | Minimed 780g, Inceptiv, Intellis Adaptivestim |
| Radius Health, INC. | $246.92 | 2021-2025 | Tymlos |
| Ascendis Pharma Endocrinology INC | $245.93 | 2024-2025 | Yorvipath |
| Sequel Med Tech, LLC | $221.46 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $189.63 | 2022-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $143.09 | 2022-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $110.32 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Kowa Pharmaceuticals America, INC. | $100.33 | 2021 | |
| Amarin Pharma, INC. | $89.09 | 2021-2023 | |
| Astellas Pharma US INC | $87.79 | 2021-2025 | Veozah |
| Nevro Corp. | $78.82 | 2021-2024 | Senza |
| Halozyme INC | $76.64 | 2023 | |
| Tolmar, INC. | $72.58 | 2025 | Jatenzo |
| Boston Scientific Corporation | $64.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $60.11 | 2022-2025 | |
| Beta Bionics, INC. | $56.29 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Vivus LLC | $52.97 | 2023-2025 | Qsymia |
| Pfizer INC. | $51.89 | 2022-2023 | |
| Zealand Pharma US, INC. | $46.76 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $42.26 | 2024-2025 | |
| Embecta Corp. | $41.36 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Rhythm Pharmaceuticals, INC. | $37.82 | 2025 | Imcivree |
| Madrigal Pharmaceuticals | $37.09 | 2025 | Rezdiffra |
| Verity Pharmaceuticals INC. | $36.11 | 2024-2025 | Tlando |
| Eusa Pharma (US) LLC | $28.61 | 2022 | |
| Currax Pharmaceuticals LLC | $27.31 | 2021-2023 | Contrave |
| Clarus Therapeutics INC. | $26.79 | 2021 | |
| Lifescan, INC. | $26.54 | 2022 | |
| Kyowa Kirin, INC. | $26.12 | 2024 | Crysvita |
| Chiesi USA, INC. | $25.17 | 2025 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $23.72 | 2024 | Strensiq |
| Arbor Pharmaceuticals, INC. | $20.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.41 | 2025 | Evkeeza |
| Soleno Therapeutics, INC. | $19.80 | 2025 | Vykat Xr |
| Almatica Pharma LLC | $19.29 | 2024 | Teriparatide, Loreev Xr |
| Grt US Holding, INC. | $19.10 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.71 | 2023 | Adthyza |
| Amryt Pharma Holdings LTD | $16.31 | 2022 | |
| Merck Sharp & Dohme LLC | $15.80 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.53 | 2023 | Crysvita |
| Endo USA, INC. | $14.47 | 2024 | Aveed |
| Ipsen Biopharmaceuticals, INC | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.